SCHEMBL6014923

SCHEMBL6014923

CCOC(=O)C(CC(=O)c1ccccc1)C(=O)OCC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.75
NPC1 O15118 3/20 0.75
MEN1 O00255 3/20 0.75
TSHR P16473 2/20 0.52
TDP1 Q9NUW8 3/20 0.51
POLB P06746 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MMP8 P22894 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
HTT P42858 1/20 0.49
PIN1 Q13526 1/20 0.49
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
PTPN1 P18031 1/20 0.47
GSK3B P49841 1/20 0.47
RAB9A P51151 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10830586 0.95 KMT2A (0.73) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL1156528 0.92 KMT2A (0.69) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL973673 0.92 KMT2A (0.69) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL2070001 0.90 KMT2A (0.67) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL8532867 0.85 KMT2A (0.60) KMT2ANPC1MEN1TDP1POLB
SCHEMBL6932566 0.84 KMT2A (0.73) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL7629504 0.84 KMT2A (0.73) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL5100197 0.84 KMT2A (0.73) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL24157601 0.84 KMT2A (0.58) KMT2ANPC1MEN1TSHRTDP1
SCHEMBL29114074 0.84 KMT2A (0.58) KMT2ANPC1MEN1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101486683-B Pyridazinone and triazinone compounds and their use as pharmaceutical formulations Sanitary Material R&D Management Co.,Ltd. (JP) 2011-12-21 CN disclosed
CN-101486683-A Pyridazinone and triazinone compounds and their use as pharmaceutical formulations EISAI R&D MAN CO LTD (JP) 2009-07-22 CN disclosed
CN-100473647-C Pyridazinone and triazinone compounds and their use as pharmaceutical formulations EISAI CO LTD (JP) 2009-04-01 CN disclosed
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-08-24 US disclosed
US-20030225081-A1 Pyridazinones and triazinones and medicinal use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-12-04 US disclosed
CN-1458924-A Pyridazinone and triazinone compounds and their use as pharmaceutical formulations EISAI CO LTD (JP) 2003-11-26 CN disclosed
EP-1319659-A1 PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF Eisai Co., Ltd. (JP) 2003-06-18 EP disclosed
US-4631280-A Pyridazine derivatives having a psychotropic action, and medicaments in which they are present SANOFI (FR) 1986-12-23 US disclosed
US-4565814-A Pyridazine derivatives having a psychotropic action and compositions SANOFI (FR) 1986-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225081-A1 Pyridazinones and triazinones and medicinal use thereof GRIK1, GRIK3, GRIK2 KMT2A 721/4885NPC1 2494/4885MEN1 3727/4885
US-20060189622-A1 Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations GRIK3, GRIK1, GRIK2 KMT2A 990/4885NPC1 2506/4885MEN1 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.